Altimmune Presents RECLAIM Trial Results at The Liver Meeting 2026

MORRISTOWN, N.J., Nov. 05, 2026 /CourierPR/ -- Altimmune, a biopharmaceutical company, announced that key data from its RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) will be presented as a late-breaking oral presentation at The Liver Meeting 2026, taking place in Denver, Colorado, on November 9, 2026. The presentation is scheduled for 10:30 a.m. MT / 12:30 p.m. ET.

The RECLAIM trial, a multicenter, randomized, double-blind, placebo-controlled study, evaluated the efficacy and safety of pemvidutide in adults with moderate-to-severe AUD. Approximately 100 patients were randomized 1:1 to receive either 2.4 mg of pemvidutide or placebo once weekly for 24 weeks. The primary endpoint of the trial was the change from baseline in the average number of heavy drinking days (HDD) per week, with secondary endpoints including the proportion of patients achieving a 2-level reduction in World Health Organization (WHO) Risk Drinking Levels (RDL), zero HDD, and absolute change from baseline in average levels of phosphatidylethanol (PEth), an objective serum biomarker of alcohol intake.

The session is scheduled for 10:30 a.m. MT / 12:30 p.m. ET on Monday, November 9, 2026.

In July 2026, Altimmune announced topline results from the RECLAIM Phase 2 trial, which showed that pemvidutide achieved the trial’s primary endpoint of a statistically significant reduction in heavy drinking days per week compared with placebo. The trial also met key secondary endpoints, including a reduction in WHO Risk Drinking Levels and zero HDD, with a generally favorable tolerability profile.

Additionally, the Company is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss the Phase 3 registrational program for pemvidutide in AUD. The company is also advancing pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).

The presentation will be accessible on the Events section of the Altimmune website immediately following the late-breaker session.

In December 2025, Altimmune announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH, was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In August 2026, the Company announced completion of enrollment of the RESTORE Phase 2 trial in ALD.

Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted as an oral presentation at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

This first presentation at an international scientific conference will feature key results from RECLAIM, a randomized, double-blind, placebo-controlled trial evaluating once-weekly pemvidutide 2.4 mg versus placebo over 24 weeks. The primary endpoint of the trial was the change from baseline in the average number of heavy drinking days (HDD) per week, with secondary endpoints including the proportion of patients achieving a 2-level reduction in World Health Organization (WHO) Risk Drinking Levels (RDL), zero HDD, and absolute change from baseline in average levels of phosphatidylethanol (PEth), an objective serum biomarker of alcohol intake. The 2-level reduction in WHO risk drinking levels and zero HDD are recognized by the FDA as registrational endpoints.

Pemvidutide is a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.